SCYNEXIS, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SCYX | MDP.TO | DERM | DMP.F | 08HH.F | 2005.HK | |
|---|---|---|---|---|---|---|
| Market cap | 38.21M | 158.39M | 133.50M | 1.93B | 5.17B | 7.63B |
| P/E (TTM) | — | — | — | 14.1 | 11.4 | 14.7 |
| Forward P/E | -1.7 | -252.0 | -78.8 | 13.1 | — | 10.6 |
| Price/book | 0.6 | 2.4 | 4.1 | 3.6 | 0.8 | 1.0 |
| Dividend yield | — | — | — | 2.26% | 2.64% | 3.24% |
| 1-year change | −19.46% | +90.19% | −47.51% | +18.72% | −24.11% | −15.48% |
| Today | −2.54% | +1.41% | +1.94% | +1.17% | +1.79% | +1.34% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All SCYX news ›SCYNEXIS (SCYX) Expected to Post Quarterly Earnings on Wednesday
Posted by Danessa Lincoln on Oct 28th, 2026 SCYX stock opened at $3.80 on Wednesday. The firm has a 50-day simple moving average of $4.64 and a 200-day simple moving average of $5.54. SCYNEXIS has a 52 week low of $3.53 and a 52 week high…
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
Intravenous means delivering a drug, fluid or substance directly into a vein so it goes straight into the bloodstream. For investors, that matters because intravenous products often act faster, require different manufacturing, regulatory…
Head-To-Head Contrast: Liquidia (NASDAQ:LQDA) and SCYNEXIS (NASDAQ:SCYX)
Posted by Kim Johansen on Oct 19th, 2026 Liquidia (NASDAQ:LQDA – Get Free Report) and SCYNEXIS (NASDAQ:SCYX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the…
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com2
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.